Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients

Summary

Patients with diabetes who undergo percutaneous coronary intervention (PCI) are at high risk for thrombotic complications following the procedure. We sought to compare the anti-thrombotic effect of bivalirudin to that of eptifibatide plus unfractionated heparin in diabetic patients undergoing elective PCI. Thirty diabetic patients were randomized to receive during PCI either bivalirudin (bivalirudin group, n=15) or eptifibatide plus heparin (eptifibatide group, n=15) at standard dosing regimens. The drugs were continued for 20 minutes (bivalirudin) or 18 hours (eptifibatide) after PCI. Blood thrombogenicity was assessed using the Badimon ex vivo perfusion chamber. Each patient underwent two perfusion studies – at baseline (on aspirin and clopidogrel) and 15–20 minutes following PCI. Perfusion studies were performed at rheologic conditions of low and high shear rates (LSR, HSR). Porcine aortic tunica media served as the thrombogenic substrate. Aortic specimens were stained for total platelet-thrombus and fibrin deposition. Thrombus area was measured using computerized planimetry. There were no differences in clinical characteristics or baseline thrombus area between the two groups. Total platelet-thrombus area was reduced significantly in both groups, but the degree of reduction was lower in the bivalirudin group compared with the eptifibatide group (HSR: 69.5% vs. 89.3% reduction, respectively, P=0.04; LSR: 50.6% vs. 73.2%, P=0.03). Fibrin deposition was reduced in both groups by 47–49%. In conclusion, both bivalirudin and the combination of eptifibatide plus heparin, given to diabetic patients during PCI, achieved marked reductions in total thrombus formation and fibrin deposition. However, glycoprotein IIb/IIIa inhibition by eptifibatide causeda more pronounced reduction in thrombus formation.

Keywords

Antithrombin - diabetes/metabolic disorders - platelet pharmacology - antiplatelet drugs - direct antithrombin agents

• References

• 1 Elezi S. et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998; 32: 1866-73.
• 2 Labinaz M. et al; ESPRIT Investigators. Comparison of one-year outcomes following coronary artery stenting in diabetic versus non-diabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin therapy [ESPRIT] trial). Am J Cardiol 2002; 90: 585-90.
• 3 Abizaid A. et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32: 584-9.
• 4 Tschoepe D. The activated megakaryocyte-platelet system in vascular disease: focus on diabetes. Semin Thromb Hemost 1995; 21: 152-60.
• 5 Keating FK. et al. Relation of augmented platelet reactivity to the magnitude of distribution of atherosclerosis. AmJ Cardiol 2004; 94: 725-8.
• 6 Yan Y, Phillips DR. Aspirin response and failure in diabetic patients with cardiovascular disease. Curr Opin Pharmacol 2005; 05: 190-7.
• 7 Giesen PL. et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-5.
• 8 Sambola A. et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 2003; 107: 973-7.
• 9 Bhatt DL. et al. Abciximab reduces mortality in diabetics following percutaneous intervention. J Am Coll Cardiol 2000; 35: 922-8.
• 10 Roffi M. et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non- ST-segment elevation acute coronary syndromes. Circulation 2001; 104: 2767-71.
• 11 Kleiman NS. et al. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence of a complex interaction in a multicenter trial. EPILOG investigators. Circulation 1998; 97: 1912-20.
• 12 Lincoff AM. et al; REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004; 292: 696-703.
• 13 Gurm HS. et al. Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial. J Am Coll Cardiol 2005; 45: 1932-8.
• 14 Lincoff AM. et al; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853-63.
• 15 Batchelor WB. et al. Randomized comparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation 2002; 106: 1470-6.
• 16 Lev EI. et al. Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function. J Am Coll Cardiol 2001; 37: 847-55.
• 17 Lev EI. et al. Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation. J Am Coll Cardiol 2004; 43: 966-71.
• 18 Dangas G. et al. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications fora potential anticoagulant effect of abciximab. Arterioscler Thromb Vasc Biol 1998; 18: 1342-9.
• 19 Kleiman NS. et al. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am HeartJ 2002; 143: 585-93.
• 20 Wittkowsky AK. The role of thrombin inhibition during percutaneous coronary intervention. Pharmacotherapy 2002; 22: 97S-104S.
• 21 Aggarwal A. et al. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention. J Thromb Thrombolysis 2002; 13: 161-5.
• 22 Keating FK. et al. The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. Coron Artery Dis 2005; 16: 401-5.
• 23 Polgar J. et al. The P-selectin, tissue factor, coagulation triad. J Thromb Haemost 2005; 03: 1590-6.
• 24 Falati S. et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet Pselectin. J Exp Med 2003; 197: 1585-98.
• 25 Del Conde I. et al. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005; 106: 1604-11.
• 26 Fernandez-Ortiz A. et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23: 1562-9.
• 27 Badimon L. et al. Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: Deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene. J Lab Clin Med 1987; 110: 706-18.
• 28 Mailhac A. et al. Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis: Relative contribution of fibrin(ogen) and platelets. Circulation 1994; 90: 988-96.
• 29 Toschi V. et al. Tissue factor modulates the thrombogenicity of atherosclerotic plaques. Circulation 1997; 95: 594-9.
• 30 Tschoepe D. et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 1991; 17: 433-8.
• 31 Keating FK. et al. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes. Thromb Res 2004; 113: 27-34.
• 32 Swords NA, Mann KG. The assembly of the prothrombinase complex on adherent platelets. Arterioscler Thromb 1993; 13: 1602-12.
• 33 Hayes R. et al. Antithrombotic effects of abciximab. Am J Cardiol 2000; 85: 1167-72.
• 34 Hamelink JK. et al. Inhibition of platelet deposition by combined hirulog and aspirin in a rat carotid endarterectomy model. J Vasc Surg 1995; 21: 492-8.
• 35 Coppinger JA. et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004; 103: 2096-104.
• 36 Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb Res 2002; 106: V275-84.
• 37 Steiner S. et al. Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression. Arterioscler Thromb Vasc Biol 2003; 23: 1697-702.
• 38 Kopp CW. et al. Abciximab reduces monocyte tissue factor in carotid angioplasty and stenting. Stroke 2003; 34: 2560-7.
• 39 Shimbo D. et al. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin. Thromb Haemost 2002; 88: 733-8.